Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Launched by AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER · Oct 31, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Colorectal cancer (CRC) is responsible for 10% of the world-wide cancer incidence and mortality. Recent data have shown that tumors arising from different regions of the colon differ in their molecular characteristics which causes translate into a differential clinical outcome.Several studies described the role of microRNA expression in the initiation and progression of CRC and its response to different therapeutic strategies. Other studies have shown that systemic inflammation is a key determinant role of clinico-pathological outcomes in patients with CRC. We therefore aim to evaluate the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Newly diagnosed Stage IV colorectal cancer
- • 2. Treatment naïve
- • 3. For the control group: adult individuals (above 18 years) with no cancer disease
- Exclusion Criteria:
- Any disease or condition that may alter the inflammatory and immune status of subjects at baseline, such as:
- • 1. Diagnosis of inflammatory bowel disease such as ulcerative colitis and crohn's disease.
- • 2. Diagnosis of active systemic autoimmune disease
- • 3. Chronic / recent use of corticosteroids
- • 4. Use of immunosuppressant drugs
About American University Of Beirut Medical Center
The American University of Beirut Medical Center (AUBMC) is a leading academic medical institution in the Middle East, dedicated to advancing healthcare through innovative research, education, and clinical excellence. As a prominent sponsor of clinical trials, AUBMC integrates cutting-edge scientific inquiry with patient-centered care to enhance therapeutic options and improve health outcomes. With a commitment to ethical standards and regulatory compliance, AUBMC collaborates with multidisciplinary teams to conduct rigorous trials that contribute to the global medical knowledge base and address critical health challenges in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beirut, , Lebanon
Patients applied
Trial Officials
Sally Temraz, MD
Principal Investigator
American University of Beirut Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials